QSAR and Molecular Docking Studies on Non-Imidazole-Based Histamine H3 Receptor Antagonists

Maryam Hamzeh-Mivehroud ¹ , Zoha Khoshravan-Azar ^2,3, Siavoush Dastmalchi ^1,2 *

Cited by CrossRef: 6

1- Shayanfar S, Shayanfar A. Comparison of various methods for validity evaluation of QSAR models. BMC Chemistry. 2022;16(1) [Crossref]

2- Mehta P, Miszta P, Filipek S. Molecular Modeling of Histamine Receptors—Recent Advances in Drug Discovery. Molecules. 2021;26(6):1778 [Crossref]

3- Jafari M, Momeni Isfahani T, Shafiei F, Senejani M. QSPR study to predict some of quantum chemical properties of anticancer imidazo[4,5‐b]pyridine derivatives using genetic algorithm multiple linear regression and molecular descriptors. Int J of Quantum Chemistry. 2024;124(1) [Crossref]

4- Jain S, Bharti S, Jagan B, Gupta A. 3D-QSAR and Pharmacophoric study on 2,6-Disubstituted Thiazolo [4,5-b] Pyridines as H3 Receptor Antagonists. RJPT. 2023;:4575 [Crossref]

5- Ghorbanpour M, Soltani B, Molavi O, Shayanfar A, Mehdizadeh Aghdam E, Ziegler C. Copper (II) complexes based bis(pyrazolyl)borate derivatives as efficient anticancer agents: synthesis, characterization, X-ray structure, cytotoxicity, molecular docking and QSAR studies. Chem Pap. 2022;76(12):7343 [Crossref]

6- Roy S, Bhowmik R, Sengupta S, Sharma S, Vyas B, A Khan I. Pharmacoinformatics Profiling and Dynamic Studies of Selected Compounds Acting as Potential Inhibitors against DPP4 Enzyme. Orient J Chem. 2021;37(5):1017 [Crossref]

Submit Your Paper Editorial Board Instructions for Authors Instructions for Reviewers Contact Us Editorial Policies Peer Review Archive

Indexing & Abstracting:

Follow us on LinkedIn
Follow us on Twitter

Director-in-Charge:
Prof. Khosro Adibkia

Editor-in-Chief:
Prof. Ali Shayanfar

Follower of ICMJE